Deferoxamine Mesylate in Ferroptosis and Immunometabolic Research

Introduction

Iron homeostasis is pivotal to cellular metabolism, oxidative stress regulation, and the delicate balance between survival and cell death. Deferoxamine mesylate (desferoxamine, SKU: B6068) stands as a canonical iron-chelating agent, renowned for its efficacy in binding free iron and preventing iron-mediated oxidative damage. With expanding research horizons, its applications now extend far beyond acute iron intoxication, encompassing hypoxia signaling, tumor growth modulation, and immunometabolic remodeling—domains at the forefront of translational science. This article offers a unique, integrative perspective on Deferoxamine mesylate, focusing on its role in ferroptosis regulation and immune microenvironment modulation, and contextualizing these advances within the latest breakthroughs in cell biology and oncology.

Mechanisms of Action: Iron Chelation, HIF-1α Stabilization, and Beyond

Iron Chelation and Oxidative Stress Protection

Deferoxamine mesylate is a hexadentate iron chelator that forms a water-soluble ferrioxamine complex, which is efficiently filtered and excreted via the kidneys. This property not only underpins its use in treating acute iron intoxication, but also enables controlled modulation of iron-dependent redox reactions in vitro and in vivo. By sequestering labile iron pools, Deferoxamine mesylate interrupts the Fenton reaction, effectively preventing iron-mediated oxidative stress—a central mediator of cellular injury in cancer, ischemia-reperfusion, and neurodegenerative models.

Hypoxia Mimetic Effects and HIF-1α Stabilization

Beyond iron chelation, Deferoxamine mesylate functions as a hypoxia mimetic agent by stabilizing hypoxia-inducible factor-1α (HIF-1α). Iron serves as a cofactor for prolyl hydroxylases, which normally target HIF-1α for degradation under normoxic conditions. By chelating iron, Deferoxamine mesylate inhibits these enzymes, resulting in robust HIF-1α accumulation and activation of hypoxic gene expression. This mechanism is instrumental in wound healing promotion—notably enhancing the regenerative capacity of adipose-derived mesenchymal stem cells—and is implicated in the cytoprotective adaptation of tissues under stress.

Ferroptosis Modulation and Tumor Growth Inhibition

Ferroptosis, an iron-dependent form of regulated cell death characterized by lethal lipid peroxidation, has emerged as a promising therapeutic target in oncology. Deferoxamine mesylate, by reducing intracellular iron availability, attenuates ferroptotic cell death, offering a dual role: as a cytoprotective agent in normal tissues and a modulator of tumor susceptibility. Notably, in preclinical models of breast cancer, Deferoxamine mesylate—especially when combined with a low-iron diet—markedly reduces tumor growth, highlighting its translational relevance as an iron chelator for acute iron intoxication and as a tool for tumor growth inhibition in breast cancer.

Deferoxamine Mesylate in the Era of Immunometabolic Remodeling and Ferroptosis

Integrating Insights from Lipid Scrambling and Tumor Immune Rejection

Recent work by Yang et al. (Science Advances, 2025) has illuminated the intricate molecular choreography occurring at the plasma membrane during ferroptosis. Their study identified TMEM16F as a suppressor of ferroptosis, orchestrating phospholipid scrambling to reduce membrane tension and mitigate damage. Notably, inhibition of this scrambling sensitizes cells to ferroptosis and, when combined with immune checkpoint blockade (PD-1), triggers robust tumor immune rejection—unveiling a new frontier in cancer immunotherapy.

In this context, Deferoxamine mesylate’s role as an iron chelator and hypoxia mimetic becomes doubly significant. By modulating the redox environment and limiting iron-catalyzed lipid peroxidation, Deferoxamine mesylate can be strategically deployed to influence both ferroptotic sensitivity and the immunogenic landscape of tumors. This intersection of iron metabolism, cell death, and immune response represents a paradigm shift, aligning with the emerging field of immunometabolic therapy.

Distinct Perspective: Beyond Existing Content

While prior reviews—such as "Deferoxamine Mesylate: Precision Iron Chelation for Advanced Translational Models"—have emphasized the broad utility of Deferoxamine mesylate in controlling oxidative stress and HIF-1α signaling, this article delves deeper into the immunometabolic consequences of ferroptosis modulation. Building upon mechanistic insights from TMEM16F-mediated lipid scrambling, we explore how Deferoxamine mesylate can be leveraged alongside targeted therapies to sculpt the tumor-immune microenvironment—a perspective not previously synthesized in the literature.

Comparative Analysis: Deferoxamine Mesylate Versus Alternative Iron Chelators and Hypoxia Mimetics

Alternative iron chelators—such as deferasirox and deferiprone—offer distinct pharmacokinetic profiles and chelation affinities. However, the unique water solubility (≥65.7 mg/mL), stability at -20°C, and high specificity for ferric iron afforded by Deferoxamine mesylate make it particularly suitable for laboratory and preclinical workflows. Moreover, its ability to stabilize HIF-1α without significant off-target toxicity distinguishes it from other hypoxia-mimetic agents (e.g., cobalt chloride), whose broader reactivity can confound experimental outcomes.

Unlike some iron chelators that may inadvertently promote ferroptosis by facilitating labile iron redistribution, Deferoxamine mesylate consistently suppresses iron-driven lipid peroxidation, aligning with its demonstrated protective effects in models of oxidative stress and tissue injury. This is especially relevant in the context of pancreatic tissue protection in liver transplantation, where oxidative injury is a major determinant of graft viability.

Advanced Applications in Translational Research

Acute Iron Intoxication and Systemic Iron Overload

Deferoxamine mesylate remains the gold standard for rapid iron chelation in acute intoxication scenarios, such as accidental ingestion or transfusional hemosiderosis. Its rapid onset, efficient renal elimination, and favorable safety profile make it indispensable in both bench and bedside contexts.

Wound Healing and Regenerative Medicine

By promoting HIF-1α stabilization and downstream angiogenic signaling, Deferoxamine mesylate enhances wound healing and tissue regeneration. This has been particularly well demonstrated in adipose-derived mesenchymal stem cell models, where the compound augments cell survival and functional recovery under hypoxic conditions. This mechanistic insight is discussed in more detail in "Deferoxamine Mesylate: Beyond Iron Chelation—Redefining Cellular Resilience"; our article extends this framework by considering how immunometabolic cues and ferroptosis interplay with tissue repair in complex disease models.

Tumor Growth Inhibition and Immune Microenvironment Modulation

Preclinical studies have highlighted the capacity of Deferoxamine mesylate to inhibit tumor progression—most notably in mammary adenocarcinoma models—by limiting iron availability and thus impeding the metabolic demands of rapidly proliferating cells. The novel dimension, illuminated by recent findings (Yang et al., 2025), is the potential for Deferoxamine mesylate to synergize with immune checkpoint inhibitors by altering the ferroptotic threshold and enhancing tumor immunogenicity. This application, which bridges iron metabolism with immunotherapy, represents an area of active investigation and significant clinical promise.

Organ Protection During Ischemia-Reperfusion and Transplantation

Oxidative injury is a principal cause of organ dysfunction following liver transplantation. Deferoxamine mesylate, by upregulating HIF-1α and inhibiting iron-mediated toxic reactions, has been shown to confer robust protection to pancreatic tissue in orthotopic liver autotransplantation models. These data reinforce the compound’s value in both experimental and translational transplantation research, as previously reviewed in "Deferoxamine Mesylate: Iron-Chelating Agent for Precision Experimental Models". Here, we further dissect the immunometabolic underpinnings of this protection, highlighting the intersection of ferroptosis, hypoxia adaptation, and immune modulation.

Practical Considerations for Experimental Design

For laboratory use, Deferoxamine mesylate is typically applied at concentrations ranging from 30 to 120 μM in cell culture systems. Solutions should be freshly prepared, given the compound’s sensitivity to prolonged storage. Its high solubility in water and DMSO (but not ethanol) affords flexibility in assay development. Proper storage at -20°C is recommended to preserve stability and chelation efficacy.

Conclusion and Future Outlook

Deferoxamine mesylate has evolved from a clinical antidote for iron overload into a sophisticated tool for dissecting iron-dependent cell death, hypoxic adaptation, and immune regulation in experimental systems. By integrating mechanistic insights from recent discoveries in lipid scrambling and ferroptosis execution (Yang et al., 2025), this article highlights how Deferoxamine mesylate can be harnessed not only to prevent iron-mediated oxidative damage but also to modulate the tumor-immune microenvironment, paving the way for next-generation combinatorial therapies.

While existing articles have underscored Deferoxamine mesylate’s applications in oxidative stress, hypoxia modeling, and ferroptosis (see here for advanced strategies), our synthesis offers a broader, systems-level perspective—emphasizing immunometabolic remodeling and translational synergy with immunotherapies. As research continues to unravel the complex interplay between iron metabolism, cell death, and immunity, Deferoxamine mesylate is poised to remain an indispensable asset in the experimentalist’s arsenal.